Clinical Trials

New clinical trial tests CAR T-cell therapy for multiple myeloma

James N. Kochenderfer, M.D., Investigator in the Surgery Branch, is leading a study of a new way to treat multiple myeloma (MM) that uses a patient’s own T cells to target MM cells. MM is a rare blood cancer that occurs in blood, tissues, bone and bone marrow. With MM, a group of plasma cells become cancerous and multiply, crowding out healthy blood cells.

Clinical trial tests combination therapy in untreated aggressive B-cell lymphomas

The Lymphoid Malignancies Branch is leading a study of a combination therapy for aggressive B-cell lymphomas using a drug that interferes with the activity of an enzyme that plays a crucial role in the development of B cells and in the cellular signaling that allows cancerous cells to multiply and survive.

Clinical Trial Conversation: Jonathan Hernandez describes metastatic colorectal cancer clinical trial

Colorectal cancer (CRC) starts in the colon and/or rectum and often metastasizes, or spreads, to many sites in the body. In a certain set of patients, however, CRC metastasizes only to the liver. Jonathan Hernandez, M.D., of the Surgical Oncology Program, is leading a new clinical trial to study how well CRC patients with liver-only metastases respond to treatment with a hepatic artery infusion pump. Dr. Hernandez describes the trial in this new video.

Clinical trial tests immunotherapy combination to treat T-cell cancers

The Center for Cancer Research’s Lymphoid Malignancies Branch is testing a combination treatment for patients whose mature T-cell cancer has returned after therapy or has not responded to therapy using avelumab, an immunotherapy agent that enhances the activity of immune cells and blocks a protein pathway that allows cancer cells to hide from the immune system.

Clinical trial will test immunotherapy against precancerous vulvar lesions

Scientists at the Center for Cancer Research are launching a phase II clinical trial to evaluate the effect of a single immunotherapy treatment on precancerous lesions that put women at risk for vulvar cancer. Like the cell-based immunotherapies now used to treat certain blood cancers, the experimental treatment aims to use patients’ own immune cells to fight disease.

Pediatric Oncology Branch patient shares neurofibromatosis journey at NIH

Xavier, a patient in the Pediatric Oncology Branch, was born with an incompletely formed leg bone and a large number of dark spots all over his body. When Xavier broke his weak leg at only 11 months of age, he was diagnosed with neurofibromatosis type 1 (NF1). He came to the NIH for treatment, and his tumors have shrunk by more than 20 percent thanks to treatment with selumetinib.

Clinical trial tests new methods for blood stem cell transplant in lymphoma

Peripheral T-cell lymphoma (PTCL) is a rare, often fast-growing cancer of white blood cells. A new clinical trial is investigating to see how a new approach to blood stem cell transplant can impact patients with PTCL.

Investigators test combination therapy for head and neck squamous cell carcinoma in new trial

Patients with recurrent head and neck squamous cell carcinoma (HNSCC) may be eligible to participate in a new clinical trial at the NIH Clinical Center. This trial tests a therapy of a novel radiosensitizer, birinapant, in combination with radiotherapy for patients whose HNSCC has come back at or near the place of the original tumor.

Clinical trial tests a new drug therapy for recurrent ependymomas of the brain and spinal cord

Ependymomas are rare tumors that arise in the ependyma, the thin membrane that lines fluid-filled cavities in the brain and spinal cord, and there are limited treatment options for those that have already been treated with standard therapies. A new clinical trial is testing a drug that targets ependymomas that have a specific genetic signature.

Clinical study follows men with specific genetic changes to determine their risk for developing prostate cancer

Prostate cancer (PC) is the most common malignancy in American men. There is increasing evidence that there may be a link between PC and men who have a family history of ovarian or breast cancer. As researchers have learned more about the role of genetics in PC, they have taken a new approach to screening for the disease—targeting men whose genetic profiles put them at risk for developing PC.

Breadcrumb